Evidence map›Paper›PMID 30701022›Full record

ArticleOncotarget2018

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.

Karine Pozo, Stefan Zahler, Keisuke Ishimatsu, Angela M Carter, Rahul Telange, Chunfeng Tan, Shuaijun Wang, Roswitha Pfragner, Junya Fujimoto, Elizabeth Gardner Grubbs and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karine PozoDepartment of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Stefan ZahlerCenter for Drug Research, Ludwig-Maximilians-Universität, Munich, Germany.
Keisuke IshimatsuAdvanced Imaging Research Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Angela M CarterDepartment of Surgery, The University of Alabama, Birmingham, AL, USA.
Rahul TelangeDepartment of Surgery, The University of Alabama, Birmingham, AL, USA.
Chunfeng TanDepartment of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shuaijun WangCenter for Drug Research, Ludwig-Maximilians-Universität, Munich, Germany.
Roswitha PfragnerInstitute of Pathophysiology and Immunology, Medical University of Graz, Graz, Austria.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth Gardner GrubbsDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Masaya TakahashiAdvanced Imaging Research Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Sarah C OltmannDepartment of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
James A BibbDepartment of Surgery, The University of Alabama, Birmingham, AL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and mortality rates have remained unchanged for decades. Increasing the repertoire of available treatments is thus crucial to manage MTC progression. Scarcity of patient samples and of relevant animal models are two challenges that have limited the development of effective non-surgical treatments. Here we use a clinically accurate mouse model of MTC to assess the effects and mode of action of the tyrosine kinase inhibitor (TKI) Vandetanib, one of only two drugs currently available to treat MTC. Effects on tumor progression, histopathology, and tumorigenic signaling were evaluated. Vandetanib blocked MTC growth through an anti-angiogenic mechanism. Furthermore, Vandetanib had an apparent anti-angiogenic effect in a patient MTC sample. Vandetanib displayed minimal anti-proliferative effects

Indexed as

animal modelmedullary thyroid carcinomatargeted therapytyrosine kinase inhibitorsvandetanib

Identifiers

PMID30701022
PMCPMC6340867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.